Physician profile
Ryan Hill
NPI 1730616988
$987.31
in general payments reported to CMS, 2019-2025
15 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.94 · 2020: $27.40 · 2021: $40.71 · 2022: $171 · 2023: $114 · 2024: $120 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $319.49 | 2022-2025 | |
| Pfizer INC. | $131.60 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $103.69 | 2021-2025 | Zerbaxa, Verquvo, Dificid |
| Gilead Sciences, INC. | $66.80 | 2022 | |
| Mylan Specialty L.P. | $52.20 | 2020-2024 | Yupelri |
| Amgen INC. | $49.38 | 2022-2024 | |
| Stryker Corporation | $40.24 | 2025 | Flowtriever |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.03 | 2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $33.67 | 2024-2025 | |
| Cvrx, INC. | $31.74 | 2025 | Barostim Neo System |
| Viatris Specialty LLC | $27.10 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $26.88 | 2025 | Uptravi |
| Astrazeneca Pharmaceuticals LP | $24.65 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $24.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $17.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.